Meadow Creek Investment Management’s Myriad Genetics MYGN Stock Holding History

Meadow Creek Investment Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$453K	Buy	15,810 +850	+6%	+$24.8K	0.01%	751
2019 Q2	$416K	Buy	14,960 +646	+5%	+$18.2K	0.01%	783
2019 Q1	$475K	Hold	14,314	–	–	0.01%	704
2018 Q4	$416K	Hold	14,314	–	–	0.01%	702
2018 Q3	$659K	Buy	14,314 +918	+7%	+$40.8K	0.01%	613
2018 Q2	$501K	Hold	13,396	–	–	0.01%	652
2018 Q1	$396K	Buy	13,396 +2,074	+18%	+$70.2K	0.01%	741
2017 Q4	$389K	Buy	11,322 +1,836	+19%	+$61.9K	0.01%	750
2017 Q3	$343K	Buy	9,486 +1,530	+19%	+$43.6K	0.01%	726
2017 Q2	$206K	Buy	7,956 +3,604	+83%	+$76.5K	﹤0.01%	866
2017 Q1	$84K	Buy	+4,352	New	+$77.1K	﹤0.01%	996

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Meadow Creek Investment Management's MYGN Position: Q3 2019 in Review

Meadow Creek Investment Management increased its Myriad Genetics (MYGN) stake by 5.7% in Q3 2019, buying an estimated $24.8K and bringing the position to 15,810 shares worth $453K. The position accounts for 0.01% of the portfolio, ranked #751.

Meadow Creek Investment Management first reported a position in MYGN in Q1 2017 and has held it in 11 quarters since. The position peaked at $659K in Q3 2018. 221 funds tracked by Wall St. Rank hold MYGN as of Q3 2019.

Meadow Creek Investment Management held 15,810 shares of Myriad Genetics worth $453K as of Q3 2019.
Meadow Creek Investment Management bought 850 Myriad Genetics shares in Q3 2019, an estimated $24.8K.
Myriad Genetics made up 0.01% of Meadow Creek Investment Management's portfolio in Q3 2019, its #751 holding.
Meadow Creek Investment Management first reported a position in Myriad Genetics in Q1 2017 and has held it in 11 quarters since.
Meadow Creek Investment Management's Myriad Genetics position peaked at $659K in Q3 2018.
221 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2019.

Based on Meadow Creek Investment Management's 13F filing for Q3 2019, filed 14 Nov 2019.